Journal article
Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial
SY Ong, LC Gurrin, L Dolling, J Dixon, AJ Nicoll, M Wolthuizen, EM Wood, GJ Anderson, GA Ramm, KJ Allen, JK Olynyk, D Crawford, LE Ramm, P Gow, S Durrant, LW Powell, MB Delatycki
Lancet Haematology | Published : 2017
Abstract
Background The iron overload disorder hereditary haemochromatosis is most commonly caused by HFE p.Cys282Tyr homozygosity. In the absence of results from any randomised trials, current evidence is insufficient to determine whether individuals with hereditary haemochromatosis and moderately elevated serum ferritin, should undergo iron reduction treatment. This trial aimed to establish whether serum ferritin normalisation in this population improved symptoms and surrogate biomarkers. Methods This study was a multicentre, participant-blinded, randomised controlled trial done at three centres in Australia. We enrolled people who were homozygous for HFE p.Cys282Tyr, aged between 18 and 70 years, ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
National Health and Medical Research Council (Australia).